Overview

Evaluation of Effectiveness of Two Different Doses of Mivacurium in Rapid Sequence Intubation

Status:
Recruiting
Trial end date:
2024-01-01
Target enrollment:
Participant gender:
Summary
Mivacurium can be considered as an optimal choice for muscle relaxation in short duration surgeries, as butyrylcholinesterase can rapidly and reliably degrade this benzylisoquinoline muscle relaxant in vivo. However the histamine release related to a rapid high-dose injection, unsatisfactory intubation conditions and unexpected delay in recovery in patients may be encountered with butyrylcholinesterase deficiency
Phase:
N/A
Details
Lead Sponsor:
Al-Azhar University
Treatments:
Mivacurium